IndraLab

Statements

Bortezomib inhibits NFKB1. 12 / 12
2 | 10
reach
"Bortezomib also effectively induced degradation of the p105 and p50 subunits of NF-kappaB in a dose dependent manner (XREF_FIG)."
| PMC
reach
"After treatment, bortezomib had up-regulated DIABLO and NFkBIB (NF-kB inhibitor), and down-regulated the NF-kB1, NF-kB2, and BIRC1, an anti-apoptotic gene (XREF_FIG)."
25913414
reach
"Furthermore, inhibition of pan-caspases abolished Bortezomib induced degradation of p65, p105 and Sp proteins, but not that of IkappaBalpha."
| PMC
reach
"This is the first report showing degradation of p105 by Bortezomib."
| PMC
reach
"These studies show that bortezomib reduces blood proteasome activity by 77% and also reduces NFKB and eNOS (nitric oxide synthase) expression following harmful ischemia."
19181875
ctd
No evidence text available
17164350
ctd
No evidence text available
12893773
reach
"Higher doses of carfilzomib were associated with higher rates of CVAE [XREF_BIBR] Ixazomib is an oral analog of Bortezomib, reversibly inhibiting the proteasome and the NFKB pathways in myeloma supporting cells, influencing cytokines important for cell growth."
33613788
reach
"In preclinical mesothelioma models, the proteasome inhibitor bortezomib inhibits constitutive activation of NFkB and enhances the cytotoxicity of cisplatin and pemetrexed [XREF_BIBR, XREF_BIBR]."
18770046
reach
"They showed that proteasome inhibitor bortezomib more effectively inhibited nuclear localization of RELA and p50 than cREL or alternate pathway subunits NF-kappaB2 or RELB in tumor specimens and lines from patients with HNSCC."
18694378
reach
"Besides IkappaBalpha and p65, we also observed degradation of p105 by Bortezomib in a dose- and time dependent manner."
| PMC
reach
"There is also evidence that lapatinib induces constitutive activation of NF-kB rendering the tumor cells more vulnerable to NF-KB inhibition by bortezomib."
31538230